Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Vaccines: All Things Considered

Vaccines: All Things Considered Ken S. Rosenthal1* and Daniel H. Zimmerman2 Northeastern Ohio Universities College of Medicine, Rootstown, Ohio 44272,1 CEL-SCI Corporation, Vienna, Virginia 221822 This minireview is based on the diverse discussions of vaccine development presented during the GTCBIO Third Annual Conference on Vaccines: All Things Considered (3 to 4 November 2005, Arlington, Va.). As the name implies, the meeting provided an excellent overview of the concepts and concerns for vaccine developers and the vaccine industry and was relevant to individuals in academia, industry, regulatory agencies, implementation, military, government, and physicians. This minireview is divided into the categories that the keynote speaker, Michel Klein (Canadian Network for Vaccines and Immunotherapeutics, Université de Montreal), indicated to be the basis for new vaccine development: (i) biological basis for vaccine development, (ii) new technologies, (iii) new targets, (iv) bringing a vaccine to market, and (v) current issues in vaccine development. Immunization programs have led to the elimination and/or control of several different infectious diseases, including smallpox, polio, measles, mumps, rubella, Haemophilus influenzae type B disease, pertussis, tetanus, and diphtheria. These vaccines were developed using technology from the 19th and 20th centuries, inactivation by heat, chemicals, and irradiation to produce a killed vaccine, vaccination with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Vaccine Immunology American Society For Microbiology

Vaccines: All Things Considered

Vaccines: All Things Considered

Clinical and Vaccine Immunology , Volume 13 (8): 821 – Aug 1, 2006

Abstract

Ken S. Rosenthal1* and Daniel H. Zimmerman2 Northeastern Ohio Universities College of Medicine, Rootstown, Ohio 44272,1 CEL-SCI Corporation, Vienna, Virginia 221822 This minireview is based on the diverse discussions of vaccine development presented during the GTCBIO Third Annual Conference on Vaccines: All Things Considered (3 to 4 November 2005, Arlington, Va.). As the name implies, the meeting provided an excellent overview of the concepts and concerns for vaccine developers and the vaccine industry and was relevant to individuals in academia, industry, regulatory agencies, implementation, military, government, and physicians. This minireview is divided into the categories that the keynote speaker, Michel Klein (Canadian Network for Vaccines and Immunotherapeutics, Université de Montreal), indicated to be the basis for new vaccine development: (i) biological basis for vaccine development, (ii) new technologies, (iii) new targets, (iv) bringing a vaccine to market, and (v) current issues in vaccine development. Immunization programs have led to the elimination and/or control of several different infectious diseases, including smallpox, polio, measles, mumps, rubella, Haemophilus influenzae type B disease, pertussis, tetanus, and diphtheria. These vaccines were developed using technology from the 19th and 20th centuries, inactivation by heat, chemicals, and irradiation to produce a killed vaccine, vaccination with

Loading next page...
 
/lp/american-society-for-microbiology/vaccines-all-things-considered-KsFljgN6Lp

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Society For Microbiology
Copyright
Copyright © 2006 by the American Society For Microbiology.
ISSN
1556-6811
eISSN
1556-6811
DOI
10.1128/CVI.00152-06
Publisher site
See Article on Publisher Site

Abstract

Ken S. Rosenthal1* and Daniel H. Zimmerman2 Northeastern Ohio Universities College of Medicine, Rootstown, Ohio 44272,1 CEL-SCI Corporation, Vienna, Virginia 221822 This minireview is based on the diverse discussions of vaccine development presented during the GTCBIO Third Annual Conference on Vaccines: All Things Considered (3 to 4 November 2005, Arlington, Va.). As the name implies, the meeting provided an excellent overview of the concepts and concerns for vaccine developers and the vaccine industry and was relevant to individuals in academia, industry, regulatory agencies, implementation, military, government, and physicians. This minireview is divided into the categories that the keynote speaker, Michel Klein (Canadian Network for Vaccines and Immunotherapeutics, Université de Montreal), indicated to be the basis for new vaccine development: (i) biological basis for vaccine development, (ii) new technologies, (iii) new targets, (iv) bringing a vaccine to market, and (v) current issues in vaccine development. Immunization programs have led to the elimination and/or control of several different infectious diseases, including smallpox, polio, measles, mumps, rubella, Haemophilus influenzae type B disease, pertussis, tetanus, and diphtheria. These vaccines were developed using technology from the 19th and 20th centuries, inactivation by heat, chemicals, and irradiation to produce a killed vaccine, vaccination with

Journal

Clinical and Vaccine ImmunologyAmerican Society For Microbiology

Published: Aug 1, 2006

There are no references for this article.